457 related articles for article (PubMed ID: 15488266)
1. Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs.
Dewulf J; Laevens H; Koenen F; Mintiens K; de Kruif A
Prev Vet Med; 2004 Oct; 65(3-4):121-33. PubMed ID: 15488266
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intradermally administrated E2 subunit vaccines in reducing horizontal transmission of classical swine fever virus.
Dortmans JC; Loeffen WL; Weerdmeester K; van der Poel WH; de Bruin MG
Vaccine; 2008 Feb; 26(9):1235-42. PubMed ID: 18242794
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the epidemiological importance of classical swine fever infected, E2 sub-unit marker vaccinated animals with RT-nPCR positive blood samples.
Dewulf J; Koenen F; Ribbens S; Haegeman A; Laevens H; De Kruif A
J Vet Med B Infect Dis Vet Public Health; 2005 Nov; 52(9):367-71. PubMed ID: 16283914
[TBL] [Abstract][Full Text] [Related]
4. Classical swine fever: comparison of oronasal immunisation with CP7E2alf marker and C-strain vaccines in domestic pigs.
Tignon M; Kulcsár G; Haegeman A; Barna T; Fábián K; Lévai R; Van der Stede Y; Farsang A; Vrancken R; Belák K; Koenen F
Vet Microbiol; 2010 Apr; 142(1-2):59-68. PubMed ID: 19857935
[TBL] [Abstract][Full Text] [Related]
5. Classical swine fever (CSF) marker vaccine. Trial I. Challenge studies in weaner pigs.
Uttenthal A; Le Potier MF; Romero L; De Mia GM; Floegel-Niesmann G
Vet Microbiol; 2001 Nov; 83(2):85-106. PubMed ID: 11557151
[TBL] [Abstract][Full Text] [Related]
6. Suitability of an E2 subunit vaccine of classical swine fever in combination with the E(rns)-marker-test for eradication through vaccination.
van Aarle P
Dev Biol (Basel); 2003; 114():193-200. PubMed ID: 14677689
[TBL] [Abstract][Full Text] [Related]
7. Detection of classical swine fever vaccine virus in blood and tissue samples of pigs vaccinated either with a conventional C-strain vaccine or a modified live marker vaccine.
Koenig P; Hoffmann B; Depner KR; Reimann I; Teifke JP; Beer M
Vet Microbiol; 2007 Mar; 120(3-4):343-51. PubMed ID: 17147979
[TBL] [Abstract][Full Text] [Related]
8. Assessment of safety and protective value of a cell culture modified strain "C" vaccine of hog cholera/classical swine fever virus.
Dahle J; Liess B
Berl Munch Tierarztl Wochenschr; 1995 Jan; 108(1):20-5. PubMed ID: 7779071
[TBL] [Abstract][Full Text] [Related]
9. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs.
de Smit AJ; Bouma A; van Gennip HG; de Kluijver EP; Moormann RJ
Vaccine; 2001 Jan; 19(11-12):1467-76. PubMed ID: 11163670
[TBL] [Abstract][Full Text] [Related]
10. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune response.
Lin GJ; Liu TY; Tseng YY; Chen ZW; You CC; Hsuan SL; Chien MS; Huang C
Vet Microbiol; 2009 Nov; 139(3-4):369-74. PubMed ID: 19625145
[TBL] [Abstract][Full Text] [Related]
11. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge.
Ganges L; Barrera M; Núñez JI; Blanco I; Frias MT; Rodríguez F; Sobrino F
Vaccine; 2005 May; 23(28):3741-52. PubMed ID: 15882536
[TBL] [Abstract][Full Text] [Related]
12. Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application.
Frey CF; Bauhofer O; Ruggli N; Summerfield A; Hofmann MA; Tratschin JD
Vet Res; 2006; 37(5):655-70. PubMed ID: 16777037
[TBL] [Abstract][Full Text] [Related]
13. Oral immunization of pigs against classical swine fever. Course of the disease and virus transmission after simultaneous vaccination and infection.
Kaden V; Schurig U; Steyer H
Acta Virol; 2001 Feb; 45(1):23-9. PubMed ID: 11394574
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs.
Tarradas J; Argilaguet JM; Rosell R; Nofrarías M; Crisci E; Córdoba L; Pérez-Martín E; Díaz I; Rodríguez F; Domingo M; Montoya M; Ganges L
Vet Microbiol; 2010 Apr; 142(1-2):51-8. PubMed ID: 19896784
[TBL] [Abstract][Full Text] [Related]
15. Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats.
Barrera M; Sánchez O; Farnós O; Rodríguez MP; Domínguez P; Tait H; Frías M; Avila M; Vega E; Toledo JR
Vet Immunol Immunopathol; 2010 Jan; 133(1):25-32. PubMed ID: 19640591
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of virus-specific peripheral blood cell cytokine responses following vaccination or infection with classical swine fever viruses.
Graham SP; Everett HE; Johns HL; Haines FJ; La Rocca SA; Khatri M; Wright IK; Drew T; Crooke HR
Vet Microbiol; 2010 Apr; 142(1-2):34-40. PubMed ID: 19854006
[TBL] [Abstract][Full Text] [Related]
17. Classical swine fever virus Strain 'C'. How long is it detectable after oral vaccination?
Kaden V; Lange E; Riebe R; Lange B
J Vet Med B Infect Dis Vet Public Health; 2004 Aug; 51(6):260-2. PubMed ID: 15458487
[TBL] [Abstract][Full Text] [Related]
18. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2).
Voigt H; Merant C; Wienhold D; Braun A; Hutet E; Le Potier MF; Saalmüller A; Pfaff E; Büttner M
Vaccine; 2007 Aug; 25(31):5915-26. PubMed ID: 17600594
[TBL] [Abstract][Full Text] [Related]
19. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV.
Maurer R; Stettler P; Ruggli N; Hofmann MA; Tratschin JD
Vaccine; 2005 May; 23(25):3318-28. PubMed ID: 15837238
[TBL] [Abstract][Full Text] [Related]
20. Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge.
Sánchez O; Barrera M; Rodríguez MP; Frías MT; Figueroa NE; Naranjo P; Montesino R; Farnos O; Castell S; Venereo A; Ganges L; Borroto C; Toledo JR
Vaccine; 2008 Feb; 26(7):988-97. PubMed ID: 18192093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
